Pieris Pharmaceuticals Inc (NASDAQ:PIRS) shares rose 0.7% during trading on Wednesday . The company traded as high as $5.85 and last traded at $5.61. Approximately 7,485 shares were traded during trading, a decline of 98% from the average daily volume of 333,922 shares. The stock had previously closed at $5.65.

PIRS has been the topic of a number of research analyst reports. HC Wainwright set a $12.00 price target on Pieris Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, June 7th. BidaskClub lowered Pieris Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, June 15th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $12.33.

The firm has a market cap of $307.46 million, a P/E ratio of -14.15 and a beta of 1.62.

Pieris Pharmaceuticals (NASDAQ:PIRS) last released its earnings results on Thursday, August 9th. The biotechnology company reported $0.00 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.01). The firm had revenue of $11.69 million for the quarter, compared to analyst estimates of $13.46 million. Pieris Pharmaceuticals had a negative return on equity of 27.81% and a negative net margin of 22.38%. research analysts expect that Pieris Pharmaceuticals Inc will post -0.49 EPS for the current fiscal year.

In other news, Director Christopher P. Kiritsy bought 5,000 shares of the stock in a transaction that occurred on Friday, September 14th. The shares were purchased at an average cost of $5.11 per share, with a total value of $25,550.00. Following the completion of the acquisition, the director now directly owns 10,000 shares in the company, valued at $51,100. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.07% of the stock is owned by insiders.

A number of large investors have recently added to or reduced their stakes in the stock. Public Employees Retirement System of Ohio acquired a new position in Pieris Pharmaceuticals during the second quarter worth about $110,000. California Public Employees Retirement System acquired a new position in Pieris Pharmaceuticals during the second quarter worth about $179,000. Alpine Global Management LLC grew its holdings in Pieris Pharmaceuticals by 125.0% during the second quarter. Alpine Global Management LLC now owns 45,000 shares of the biotechnology company’s stock worth $228,000 after acquiring an additional 25,000 shares during the period. Marshall Wace LLP acquired a new position in Pieris Pharmaceuticals during the second quarter worth about $118,000. Finally, Aquilo Capital Management LLC acquired a new position in Pieris Pharmaceuticals during the second quarter worth about $10,013,000. 64.93% of the stock is currently owned by hedge funds and other institutional investors.

About Pieris Pharmaceuticals (NASDAQ:PIRS)

Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.

Read More: What is the NASDAQ?

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.